A potential 40% cost savings through treating cidp with tpe instead of ivig

Conclusions TPE is cheaper than IVIg for CIDP with respect to what is paid by DHB’s to the NZBS. It is unknown if similar cost savings exist in other healthcare systems. Potentially, IVIg may not need to be continued at full doses for an entire year and similarly TPE may not need to be continued at the same frequency. To address issues such as convenience of therapy and total patient care costs a prospective evaluation is needed. Furthermore, as there are no head-to-head IVIG-to-TPE studies in CIDP, the long-term efficacy of TPE in treating CIDP requires evaluation.

http://jnnp.bmj.com/cgi/content/short/88/5/e1-v?rss=1

Source: Journal of Neurology, Neurosurgery and Psychiatry - May 8, 2017 Category: Neurosurgery Authors: Parry, G. J., Buenz, E. J., Ranta, A. Tags: Abstracts Source Type: research